VDK Biotech, with synthetic biology as its core technological pathway, has been deeply engaged in the industrialization of synthetic biology and is a platform-based enterprise with full industrial chain operational capabilities. The company has established a fully independent and controllable system encompassing the entire process-from bioenzyme mining and optimization, metabolic pathway regulation and engineering, autonomous strain construction, pilot-scale fermentation and scale-up, pilot-scale separation and extraction, to industrial-scale production and market application. All supporting fixed assets for production are independently invested in and constructed by the company. Its business focuses on high-value-added sectors such as high-end fragrances, nutritional and health ingredients, and natural pigments. Leveraging its self-developed microbial cell factory technology, VDK has achieved large-scale bio-manufacturing of various natural products, including the sclareol series (sclareol, sclareol glycol), resveratrol, 5-hydroxytryptophan (5-HTP), astaxanthin, beta-carotene, and canthaxanthin.